Commercial Credit Report for Launxp Biomedical Co Ltd

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for Launxp Biomedical Co Ltd is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	Launxp Biomedical Co Ltd

Phone: +886 423205691p:+886 423205691	TAICHUNG, 408 Taiwan	Ticker: 68766876

Business Summary

Launxp Biomedical Co Ltd is a Taiwan-based company mainly engaged in the development of new drugs. The Company mainly develops cancer drugs. The main products include LXPA1788, LXPA1988, LXPA5948, LXPB5268, LXPB5101, LXPB8101, LXPB9568, LXPB977 and others. LXPA1788 is a new ingredient and new drug, a multi-target kinase inhibitor. LXPA1988 is a new ingredient and new drug with a novel chemical structure. It exhibits high inhibitory activity against the fms-like tyrosine kinase 3 (FLT3) kinase and its mutations, inhibiting FLT3 signaling in acute myeloid leukemia (AML) cancer cells and thereby inhibiting tumor growth. LXPA5948 is a new ingredient and new drug. LXPB5268 is a new drug for new indications. LXPB5101, LXPB8101, LXPB9568, and LXPB977 are new drugs with new indications and new dosage forms.

(Source: N-30D)

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
Yes	Yes	-	Yes	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
12/31/2023	12/31/2023	Yes	-	-	-	-

Industries

SIC Code	Description
2834	Pharmaceutical preparations
8731	Commercial physical and biological research

Officers and Directors

Title	Name	Age	Title Date	Start Date
Head of Finance	ShifengYan		4/16/2023	4/16/2023

General Information

Outstanding Shares:	32,188,749	(As of 1/18/2024)
Stock Exchange:	TPO
Fax Number:	+886 423205693

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN